| Autor: |
Shah SR; Department of Internal Medicine, North Florida Regional Medical Center, University of Central Florida, Gainesville, FL, USA., Najim NI; Department of Internal Medicine, National Children Hospital, Washington DC, USA., Abbasi Z; Department of Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan., Fatima M; Department of Internal Medicine, Post Doc Fellow Cardiology at Beth Israel Deaconess Medical Center, Boston, USA., Jangda AA; Department of Internal Medicine, Ziauddin Medical University Hospital, Karachi, Pakistan., Shahnawaz W; Department of Internal Medicine, Agha Khan University Hospital, Karachi, Pakistan., Shahid M; Department of Internal Medicine, Dow University of Health Sciences (DUHS), Karachi, Pakistan., Shah SA; Department of Internal Medicine, Ziauddin Medical University Hospital, Karachi, Pakistan. |
| Abstrakt: |
Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in individuals with hyperglycemia. Before the approval of canagliflozin by the Food and Drug Administration (FDA) in 2013, a pair-wise meta-analyses of trials involving canagliflozin did not differ from control in terms of all-cause mortality, cardiovascular death, myocardial infarction, and stroke. However, no large, randomized-controlled trials were available for comparison until the results of the CANVAS (Canagliflozin Cardiovascular Assessment Study) trial were published. The CANVAS Trial was designed to assess the cardiovascular safety and efficacy of canagliflozin. Recently, results of the completed CANVAS Trial were released which showed patients with type 2 diabetes and established cardiovascular disease or at high risk for cardiovascular events who were treated with canagliflozin had significantly lower rates of the primary cardiovascular outcome than patients assigned to placebo. All three components of the primary outcome - death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke - showed point estimates of effect that suggested benefit .These results may represent a significant additional therapeutic tool in the clinical prevention and management of cardiovascular mortality and morbidity. However, data on the long-term efficacy on the use of Canagliflozin is still incomplete and their use in patients with type 2 diabetes should be carefully considered. |
